Director, Molecular Pathology, Translational Sciences, Translational Research.

Benefits

Parental leave

Not verified

Non-birth-parent leave

Not verified

Family-building benefits

• Fertility benefits: Not verified
• Adoption assistance: Not verified
• Surrogacy assistance: Not verified

Mental health support

Not verified

Relocation assistance

Not verified

Childcare support

Not verified

Learning budget

Not verified

Verification

Not verified

Salary

Not verified not verified - source not recorded; timestamp not recorded

401(k) match

Not verified

Was this benefit information wrong? Tell us.

Market context

Median wage (BLS OEWS)

$111,944 national median

Projected growth (BLS Employment Projections)

+13.7% - Much faster than average

112% above the BLS national median for data and ml aggregate.

Matched to SOC 15-1252 - Data and ML aggregate by role bucket.

Source: U.S. Bureau of Labor Statistics, OEWS, May 2024 and Employment Projections, 2024-2034.

Schedule

Shift type

Not verified

Weekend work

Not verified

Application

Cover letter

Not verified

Assessment

Not verified

Deadline

Not stated

Where they hire

State eligibility is not yet verified.

About this role

Director, Molecular Pathology, Translational Sciences, Translational Research. Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: As a Director, Molecular Pathology, you will be a key member of a cross-functional Translational Sciences Team, reporting to the Senior Director and Head of Translational Sciences within Translational Research and will: - Biomarker Strategy: Define and execute molecular and digital pathology-driven biomarker strategies. - Integration of Advanced Modalities: Lead adoption of molecular pathology and spatial technologies (to support translational research and broader BDR needs. - Digital & Computational Pathology: Drive implementation of whole-slide imaging, AI/ML-based image analysis, and integration of spatial biomarker analytics into decision-making. - Data Interpretation & Reporting: Provide expert interpretation of pathology data, ensuring robust correlation with clinical outcomes and mechanistic insights. - Cross-functional Leadership: Collaborate with Translational Medicine, Bioinformatics, and Clinical Development colleagues to implement candidate biomarkers into Translational Biomarker plans for RAS(ON) inhibitors in alignment with overarching clinical development strategies. Responsibilities - Scientific Leadership

Read the full description at www.revmed.com. FewerJobs shows a source-linked preview and links to the original posting.